Indian generics start reshaping GLP-1 share in the world's most price-sensitive market

India's GLP-1 weight-loss and diabetes drug market is being reshaped by a wave of low-cost generic semaglutide, and the early data show it is Eli Lilly, not Novo Nordisk, losing the most ground. Eli Lilly's market share fell to 56% in March from 61% in February, while Novo Nordisk held steady at 25%, according to data from industry intelligence provider Pharmarack cited by CNBC ^[1].

The shift followed the March expiration of the patent on semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, which triggered a rush of Indian copies ^[1]. Within weeks, 13 Indian generic drugmakers launched 26 brands of semaglutide, according to the Pharmarack report ^[1]. Analysts had expected the flood of cheap semaglutide to hurt Novo Nordisk the most, but early figures instead show tirzepatide, Eli Lilly's drug sold as Mounjaro, losing share ^[1].

The reason comes down to price. Mounjaro starts at about 13,800 rupees, or roughly $148, a month in India, said Mumbai-based diabetologist Rajiv Kovil, who noted that is more than double the cost of Novo's semaglutide products and about ten times the price of the cheapest generic versions ^[1]. Vishal Manchanda, a pharma analyst at Systematix Group, said "the widening cost differential between semaglutide and tirzepatide, along with publicity around cheaper semaglutide generics," is driving the erosion of Eli Lilly's share ^[1]. He added that tirzepatide may increasingly be limited to wealthier patients focused on weight loss, since it remains more effective but costs more ^[1].

Novo Nordisk has also cut its own prices to compete. The company reduced the price of Ozempic by 38% and Wegovy by 48% in India, according to a March 31 press release cited by CNBC ^[1]. Novo Nordisk India managing director Vikrant Shrotriya said the goal was to keep the drugs "affordable for as many people with type 2 diabetes, overweight and obesity in India as possible" ^[1]. After the cuts, Novo's semaglutide products start at 5,660 rupees a month, compared with about 4,200 rupees for higher-end generics, and as little as 1,290 rupees for some generic versions, according to Anant Kharad of Anand Rathi Investment Banking ^[1].

Why it matters for patients

None of these Indian generic semaglutide products are sold in the United States, where Ozempic, Wegovy, Mounjaro and Zepbound remain patent-protected brand-name drugs with U.S. list prices far above what is charged in India. But the India data offers a preview of what can happen to prices and market share once patents lapse and multiple manufacturers compete on cost. It also underscores that price, not just effectiveness, can quickly move patients and prescribers, since Kovil said the shift toward generics is most pronounced among people seeking fast results rather than long-term treatment ^[1]. U.S. patients weighing tirzepatide against semaglutide products should know that cost pressure abroad does not change U.S. pricing or availability today, and any generic versions in India have not gone through U.S. regulatory review.

What happens next

Analysts expect India's GLP-1 market to keep growing quickly, potentially nearly fivefold to 50 billion rupees by 2030, with some bullish estimates topping $1.2 billion, as more generic makers seek regulatory clearance and demand concentrates among four or five leading companies, including Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Dr. Reddy's Laboratories and Zydus Lifesciences, according to Kharad ^[1]. Kharad said physician confidence in generic quality will be the key variable to watch over the next 12 to 18 months ^[1].